Loading clinical trials...
Loading clinical trials...
A Phase 2 Study of Suberoylanilide Hydroxamic Acid (SAHA) in Subjects With Locally Advanced, Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC)
Conditions
Interventions
Laboratory Biomarker Analysis
Vorinostat
Locations
12
United States
City of Hope Comprehensive Cancer Center
Duarte, California, United States
City of Hope South Pasadena
South Pasadena, California, United States
Yale University
New Haven, Connecticut, United States
National Institutes of Health Clinical Center
Bethesda, Maryland, United States
Wayne State University/Karmanos Cancer Institute
Detroit, Michigan, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Start Date
August 6, 2010
Primary Completion Date
June 8, 2018
Completion Date
August 1, 2018
Last Updated
August 3, 2020
NCT04895735
NCT05669664
NCT03146650
NCT01254617
NCT00859937
NCT00458978
Lead Sponsor
National Cancer Institute (NCI)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions